Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.
Cranbury, NJ
Joined February 2009
- Tweets23.8K
- Following789
- Followers30.2K
- Likes3.8K
Pinned Tweet
“Every oncologist, every researcher, every IRB has got to know about that study.”
@DrMaurieMarkman, on why LACC tops his ranking of landmark gynecologic oncology trials on Double Blind.
Watch: youtube.com/watch?v=4KcWCXiR…
The robotic endoscopy system obtained detrusor muscle in 94% of resected bladder lesions among the first 20 patients treated in the VIABLE study.
hubs.ly/Q04F2SBy0
#blcsm #BladderCancer #oncology #cancer
1
116
Pasritamig plus JNJ-9401 reduced PSA levels by at least 50% in 73% of heavily pretreated patients with metastatic castration-resistant prostate cancer.
hubs.li/Q04DXzXD0
#pcsm #ProstateCancer #oncology #cancer
172
🎙️ On Oncology On the Go, @Jani_Chinmay discusses lung cancer in younger adults who have never smoked and how molecular testing may guide treatment.
Listen on Apple Podcasts, Spotify, or at:
hubs.li/Q04D_qjN0
#LungCancer #ThoracicOncology #PrecisionOncology
CancerNetwork® retweeted
Excited to be joining CancerNetwork as a medical correspondent at the 44th Annual Chemotherapy Foundation Symposium (#CFS2026) in New York City!
Looking forward to engaging with leading experts in oncology, discussing emerging clinical evidence, and highlighting the scientific advances shaping the future of cancer care.
It's a privilege to help bring these conversations and expert perspectives to the broader oncology community.
Grateful to the CancerNetwork, OncLive, and PER teams for the opportunity to contribute to meaningful scientific dialogue and education.
Looking forward to an exciting few days of learning, collaboration, and conversations at the forefront of oncology!
#CFS2026 #CancerNetwork #Oncology #CancerResearch #CancerCare #MedicalEducation @CancerNetwrk @gotoPER @OncLive
MedNews Week will be on the ground in New York City starting tomorrow for the 44th Annual Chemotherapy Foundation Symposium (#CFS2026)! 🗽
Led by Dr. Yan Leyfman, our team will be bringing you the latest insights, expert perspectives, and engaging conversations on emerging advances in cancer research and treatment.
Looking forward to seeing our team connect with leaders in oncology and share meaningful discussions with the global medical community.
Stay tuned for exclusive coverage from NYC!
@MedNewsWeek @YLeyfman @shahzeenkadir1 @The_Noam_Levi @OncLive
#MedNewsWeek #Oncology #CFS2026
The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.
hubs.li/Q04DXVQ_0
#oncology #cancer #crcsm #gyncsm
The @FDA has approved pimicotinib (Pimjetmi) as treatment for patients with tenosynovial giant cell tumor (TGCT) for whom surgical resection may lead to worsening functional limitation or severe morbidity. Data from the phase 3 MANEUVER trial supported the regulatory decision.
cancernetwork.com/view/fda-a…
#TGCT #Oncology | @FDADrugs
In case you missed it: at #ESMO26 in Madrid, CancerNetwork® spoke with 3 experts about key questions in breast, lung, and kidney cancer.
🔹 @hoperugo on safety findings from KEYNOTE-B49 and what’s next with TroFuse-010 in HR-positive, HER2-negative metastatic breast cancer
🔹 @matt_cw_lee on how the CEACAM5-targeting ADC BG-C477 stands apart in NSCLC
🔹 Shankar Siva, PhD, MBBS, FRANZCR, on when to consider cytoreductive SABR in primary metastatic kidney cancer
Watch the full video: youtu.be/voaVWkygsVU
#bcsm #lcsm #kcsm
Among 55 efficacy-evaluable patients with PD-(L)1–resistant/refractory NSCLC, treatment demonstrated dose-dependent activity across the 1-, 3-, and 10-mg/kg every-3-weeks dose levels.
hubs.li/Q04DQjbM0
#lcsm #NSCLC #oncology #cancer
159
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
hubs.li/Q04DFCSd0
#pcsm #prostatecancer #oncology #cancer
220
51% of patients with refractory microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months after starting botensilimab plus balstilimab.
hubs.li/Q04DFzCP0
#crcsm #oncology #cancer
1
155
Adding tambiciclib to azacitidine and venetoclax yielded encouraging responses in prelapsed or refractory acute myeloid leukemia that previously progressed on venetoclax-based therapy.
hubs.li/Q04DFBhl0
#leusm #leukemia #oncology #cancer
152
🚨 A new top 5 has dropped!
1. hubs.li/Q04DFym70
2. hubs.li/Q04DFyp50
3. hubs.li/Q04DFym80
4. hubs.li/Q04DFym90
5. hubs.li/Q04DFy4w0
#melsm #pcsm #gicsm #oncology #cancer
2
255
How are treatment goals evolving in newly diagnosed multiple myeloma?
In CancerNetwork's Between the Lines, Drs. Saad Usmani (@szusmani) and Shaji Kumar (@myelomaMD) discuss MRD negativity, quadruplet regimens, and treatment considerations for older patients.
▶️ Watch now: hubs.li/Q04Cb-DS0
#MultipleMyeloma
What’s one thing about hepatocellular carcinoma (HCC) you wish more of your colleagues knew? 🩺
At #TLM26 in Denver, we put that question to 4 liver cancer specialists: @DrHuangDQ, @AndrewMMoon, Laura Kulik, MD, and Neil Mehta, MD.
Hear what they had to say about awareness gaps in HCC care.
#HCC #LiverCancer #Hepatology #Oncology #TheLiverMeeting #AASLD
1
1
277
Up to a third of patients with MASLD-related HCC don’t have cirrhosis, so surveillance limited to cirrhosis misses them.
At #TLM2026, @DrHuangDQ of @NCIS_NUHS talked about how genetics, body composition, and multidisciplinary pathways should shape care.
cancernetwork.com/view/rethi…
#MASLD #LiverCancer #HCC
1
1
246
🚨 The latest edition of the Weekly Roundup is here!
📖 Check out this week's newsletter for a breakdown of our coverage from the @UPMCHillmanCC Radiation Oncology Symposium!
Subscribe on LinkedIn hubs.li/Q04DFwzy0
#oncology #RadOnc #cancer
196
MASLD is driving more liver cancer, and surveillance isn’t keeping up. Up to a third of ultrasounds in these patients may be low quality.
At #TLM2026, @SeragHashem of @bcmhouston talked about who needs HCC screening, the role of GLP-1 receptor agonists, and what comes next.
cancernetwork.com/view/build…
#MASLD #LiverCancer #HCC
Today, CancerNetwork is live from Denver at #TLM26!
Watch for coverage, including interviews with Anjana Pillai, MD, of @UChicagoMed and Ryosuke Tateishi, MD, PhD, FAASLD, of the University of Tokyo on liver cancer prevention.
#LiverCancer #HCC
225